

Suzanne Arends

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4513018/publications.pdf>

Version: 2024-02-01

105
papers

3,013
citations

159358

30
h-index

182168

51
g-index

107
all docs

107
docs citations

107
times ranked

3703
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e148-e148.	0.5	1
2	Histopathology, salivary flow and ultrasonography of the parotid gland: three complementary measurements in primary Sjögren's syndrome. <i>Rheumatology</i> , 2022, 61, 2472-2482.	0.9	12
3	Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151955.	1.6	13
4	Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151974.	1.6	9
5	Central sensitization has major impact on quality of life in patients with axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151933.	1.6	16
6	Letter to the editor: Prevalence of connective tissue disease autoantibodies in a large longitudinal population-based cohort from the Netherlands. <i>Autoimmunity Reviews</i> , 2022, 21, 103063.	2.5	0
7	Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 33-38.	0.4	8
8	Change in disease activity is associated with TNF- α inhibitor serum levels in patients with axial spondyloarthritis in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 489-494.	0.4	1
9	Digital image analysis of intraepithelial B-lymphocytes to assess lymphoepithelial lesions in salivary glands of Sjögren's syndrome patients. <i>Rheumatology</i> , 2022, 62, 428-438.	0.9	2
10	Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome. <i>RMD Open</i> , 2022, 8, e002265.	1.8	5
11	Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus. <i>Joint Bone Spine</i> , 2022, 89, 105381.	0.8	2
12	Differences in characteristics, health status and fulfillment of exercise recommendations between axial spondyloarthritis patients with and without supervised group exercise. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152035.	1.6	1
13	Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 644-651.	1.1	4
14	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). <i>Rheumatology</i> , 2021, 60, 658-666.	0.9	7
15	Clinical Phenotyping of Primary Sjögren Syndrome Patients Using Salivary Gland Ultrasonography: Data From the RESULT Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 717-727.	1.0	15
16	Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 153-160.	0.6	4
17	Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*. <i>British Journal of Dermatology</i> , 2021, 185, 177-184.	1.4	18
18	CD27-CD38 ^{low} CD21 ^{low} B-Cells Are Increased in Axial Spondyloarthritis. <i>Frontiers in Immunology</i> , 2021, 12, 686273.	2.2	15

#	ARTICLE	IF	CITATIONS
19	Extra-skeletal manifestations in axial spondyloarthritis are associated with worse clinical outcome despite the use of TNF blocking therapy. <i>Journal of Rheumatology</i> , 2021, , jrheum.210308.	1.0	7
20	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology</i> , The, 2021, 3, e553-e562.	2.2	31
21	The mSQUASH; a valid, reliable and responsive questionnaire for daily physical activity in patients with axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 719-727.	1.6	5
22	Composite endpoints for Sjögren's Syndrome – Authors' reply. <i>Lancet Rheumatology</i> , The, 2021, , .	2.2	0
23	Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, 4476-4485.	0.9	19
24	Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort. <i>Lupus Science and Medicine</i> , 2021, 8, e000555.	1.1	3
25	Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	1
26	Change in disease activity is associated with TNF- α inhibitor serum levels in patients with axial spondyloarthritis in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
27	Clinical determinants of vaginal dryness in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
28	Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
29	Differences in presentation between paediatric- and adult-onset primary Sjögren's syndrome patients. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
30	Clinical determinants of vaginal dryness in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 73-79.	0.4	3
31	Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 100-106.	0.4	3
32	Differences in presentation between paediatric- and adult-onset primary Sjögren's syndrome patients. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 85-92.	0.4	2
33	Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 38-46.	0.6	7
34	Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020, 72, 583-590.	1.5	50
35	Fracture Risk Reduction by Bisphosphonates in Mastocytosis?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3557-3564.	2.0	6
36	Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). <i>Lancet Rheumatology</i> , The, 2020, 2, e153-e163.	2.2	51

#	ARTICLE	IF	CITATIONS
37	10-year follow-up of patients with rheumatoid arthritis and secondary Sjögren's syndrome or sicca symptoms in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 64-72.	0.4	4
38	Recent insights in the potential role of imaging modalities for diagnosing patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 310-314.	0.4	2
39	Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF- α inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 828-833.	1.6	13
40	High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 611-617.	1.6	24
41	High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor- α blocking therapy in ankylosing spondylitis. <i>Rheumatology</i> , 2019, 58, 1040-1046.	0.9	16
42	OP0045...ABATACEPT TREATMENT OF PATIENTS WITH EARLY ACTIVE PRIMARY SJÖGREN'S SYNDROME - A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE. , 2019, , .		2
43	FRI0381...TROUGH SERUM DRUG LEVELS AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS PATIENTS ON LONG-TERM TREATMENT WITH TNF- α INHIBITORS. , 2019, , .		0
44	SAT0357...PREVALENCE OF RADIOGRAPHIC ENTHESEAL LESIONS AT THE HIP AND PELVIC REGION IN PATIENTS WITH ANKYLOSING SPONDYLITIS. , 2019, , .		1
45	High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 551-554.e1.	0.6	11
46	Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e27-e27.	0.5	6
47	Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 42-48.	0.4	9
48	Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity. <i>Lupus</i> , 2018, 27, 1271-1278.	0.8	7
49	Validation of the ACR-EULAR criteria for primary Sjögren's syndrome in a Dutch prospective diagnostic cohort. <i>Rheumatology</i> , 2018, 57, 818-825.	0.9	27
50	Social Role Participation and Satisfaction With Life: A Study Among Patients With Ankylosing Spondylitis and Population Controls. <i>Arthritis Care and Research</i> , 2018, 70, 600-607.	1.5	15
51	Ultrasound of the Major Salivary Glands is a Reliable Imaging Technique in Patients with Clinically Suspected Primary Sjögren's Syndrome. <i>Ultraschall in Der Medizin</i> , 2018, 39, 328-333.	0.8	20
52	The parotid gland connection: ultrasound and biopsies in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e38-e38.	0.5	11
53	Scoring hypoechoic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 556-562.	0.5	32
54	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018, 4, e000755.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF- α inhibitors. PLoS ONE, 2018, 13, e0196281.	1.1	11
56	Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome. Rheumatology, 2018, 57, 1812-1821.	0.9	28
57	Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome. Journal of Rheumatology, 2017, 44, 292-296.	1.0	11
58	Identification of Lifelines participants at high risk for development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, e43-e43.	0.5	2
59	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Annals of the Rheumatic Diseases, 2017, 76, 1184-1190.	0.5	73
60	Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Arthritis Research and Therapy, 2017, 19, 77.	1.6	18
61	Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 1850-1861.	2.9	134
62	Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor- α Blocking Therapy in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2017, 44, 587-593.	1.0	11
63	Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1883-1889.	0.5	103
64	Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF- α inhibitors: Facet joints vs. vertebral bodies. Seminars in Arthritis and Rheumatism, 2017, 46, 562-568.	1.6	22
65	B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome. Journal of Rheumatology, 2017, 44, 49-58.	1.0	48
66	Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. Arthritis Care and Research, 2017, 69, 694-702.	1.5	36
67	Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors. Arthritis Care and Research, 2017, 69, 1011-1019.	1.5	77
68	Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF- α inhibitors. PLoS ONE, 2017, 12, e0177231.	1.1	33
69	Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis. PLoS ONE, 2017, 12, e0182549.	1.1	10
70	Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clinical and Experimental Rheumatology, 2017, 35, 61-68.	0.4	15
71	Physical fatigue characterises patient experience of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 255-261.	0.4	8
72	Dental Implants in Patients with Sjögren's Syndrome. Clinical Implant Dentistry and Related Research, 2016, 18, 937-945.	1.6	28

#	ARTICLE	IF	CITATIONS
73	Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. <i>RMD Open</i> , 2016, 2, e000177.	1.8	7
74	Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-sectional Comparison With Population Controls. <i>Arthritis Care and Research</i> , 2016, 68, 1899-1905.	1.5	15
75	Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome. <i>Journal of Rheumatology</i> , 2016, 43, 383-387.	1.0	68
76	Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF- β blocking therapy. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 191-9.	0.4	7
77	Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF- β Blocking Therapy: A Prospective Longitudinal Observational Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0122693.	1.1	46
78	Quantifying Distribution of Flow Cytometric TCR- β Usage with Economic Statistics. <i>PLoS ONE</i> , 2015, 10, e0125373.	1.1	39
79	Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2015, 94, e1542.	0.4	93
80	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. <i>Journal of Rheumatology</i> , 2015, 42, 2369-2375.	1.0	25
81	The impact of primary Sjögren's syndrome on female sexual function. <i>Rheumatology</i> , 2015, 54, 1286-1293.	0.9	61
82	Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort: Table 1. <i>Rheumatology</i> , 2015, 54, 1333-1335.	0.9	10
83	Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 792-798.	1.5	13
84	Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. <i>Rheumatology</i> , 2015, 54, 1397-1402.	0.9	83
85	Patient-tailored dose reduction of TNF- β blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 174-80.	0.4	20
86	Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 443-4.	0.4	12
87	Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis. <i>PLoS ONE</i> , 2014, 9, e99685.	1.1	25
88	Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1413-1421.	1.5	28
89	Clinical studies on bone-related outcome and the effect of TNF- β blocking therapy in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 259-268.	2.0	18
90	Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of) Tj ETQq0 0.0 rgBT /Overlock 205	0.5	205

#	ARTICLE	IF	CITATIONS
91	EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 472-474.	0.5	34
92	Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R36.	1.6	35
93	Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments. <i>Arthritis Research and Therapy</i> , 2013, 15, R99.	1.6	49
94	Prevalence of indolent systemic mastocytosis in a Dutch region. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1429-1431.e1.	1.5	78
95	Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire. <i>PLoS ONE</i> , 2013, 8, e55912.	1.1	23
96	Baseline predictors of response to TNF- α blocking therapy in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 290-298.	2.0	33
97	Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1297-1302.	0.5	99
98	Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 966-973.	0.5	56
99	Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 683-690.	2.7	54
100	The effect of three years of TNF-alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. <i>Arthritis Research and Therapy</i> , 2012, 14, R98.	1.6	42
101	Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R94.	1.6	179
102	The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. <i>Osteoporosis International</i> , 2011, 22, 1431-1439.	1.3	89
103	Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 1644-1650.	1.0	40
104	Monitoring stress and recovery: new insights for the prevention of injuries and illnesses in elite youth soccer players. <i>British Journal of Sports Medicine</i> , 2010, 44, 809-815.	3.1	191
105	Balance confidence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2450-2451.	2.2	12